Active — Not RecruitingPhase 1

A Study of LY3200882 in Participants With Solid Tumors

United States, Australia223 participantsStarted 2016-11-21

Plain-language summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * The participant must have histological or cytological evidence of cancer. * Have adequate organ function. * Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1. * Are able to swallow capsules and tablets. Exclusion Criteria: * Have moderate or severe cardiovascular disease. * Have a serious concomitant systemic disorder. * Have acute leukemia.

What they're measuring

Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)

Timeframe: Cycle 1 (28 days)

Part B: Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR)

Timeframe: Baseline through Disease Progression or Death (estimated at up to 12 months)

Trial details

NCT IDNCT02937272

SponsorEli Lilly and Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-02-27

View on ClinicalTrials.gov More Solid Tumor trials